Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 5, 1998, Pages 621-628

  Yang, B ^a   Koga, H ^a   Ohno, H ^a   Ogawa, K ^a   Fukuda, M ^a   Hirakata, Y ^a   Maesaki, S ^a   Tomono, K ^a   Tashiro, T ^a   Kohno, S ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; RIFABUTIN; RIFALAZIL; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CODON; CONTROLLED STUDY; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; POINT MUTATION; PREDICTION; STRAIN DIFFERENCE; TUBERCULOSIS;

EID: 0031795962     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.5.621     Document Type: Article

References (36)

1. Sudre, P., ten-Dam, G. & Kochi, A. (1992). Tuberculosis: a global overview of the situation today. Bulletin of the World Health Organization 70, 149-59.
2. Brudney, K. & Dobkin, J. (1991). Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. American Review of Respiratory Disease 144, 745-9.
3. Beck-Sague, C., Dooley, S. W., Hutton, M. D., Otten, J., Breeden, A., Crawford, J. T. et al. (1992). Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. Journal of the American Medical Association 268, 1280-6.
4. Dooley, S. W., Jarvis, W. R., Martone, W. J. & Snider, D. E. (1992). Multidrug-resistant tuberculosis. Annals of Internal Medicine 117, 257-9.
5. Fischl, M. A., Uttamchandani, R. B., Daikos, G. L., Poblete, R. B., Moreno, J. N., Reyes, R. R. et al. (1992). An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Annals of Internal Medicine 117, 117-83.
6. Bloch, A. B., Cauthen, G. M., Onorato, I. M., Dansbury, K. G., Kelly, G. D., Driver, C. R. et al. (1994). Nationwide survey of drug resistant tuberculosis in the United States. Journal of the American Medical Association 271, 665-71.
7. Edlin, B. R., Tokars, J. I., Grieco, M. H., Crawford, J. T., Willimas, J., Sordillo, E. M. et al. (1992). An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 326, 1514-21.
8. Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M. & Dooley, S. W. (1993). The emergence of drug-resistant tuberculosis in New York City. New England Journal of Medicine 328, 521-6.
9. Gangadharam, P. R. J., Perumal, V. K., Jairam, B. T., Rao, P. N., Nguyen, A. K., Farhi, D. C. et al. (1987). Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. American Review of Respiratory Disease 136, 329-33.
10. Ji, B., Truffot-Pernot, C., Lacroix, C., Raviglione, M. C., O'Brien, R. J., Olliaro, P. et al. (1993). Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. American Review of Respiratory Disease 148, 1541-6.
11. O'Brien, R. J., Geiter, L. J. & Lyle, M. A. (1990). Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex. American Review of Respiratory Disease 141, 821-6.
12. O'Brien, R. J., Lyle, M. A. & Snider, D. E. (1987). Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Reviews of Infectious Diseases 9, 519-30.
13. Saito, H., Tomioka, H., Sato, K., Emori, M., Yamane, T. & Yamashita, K. et al. (1991). In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy 35, 542-7.
14. Saito, H., Tomioka, H., Sato, K., Kawahara, S., Hidaka, T. & Dekio, S. (1995). Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tubercle and Lung Disease 76, 51-8.
15. Tomioka, H., Saito, H., Sato, K., Yamane, T., Yamashita, K., Hosoe, K. et al. (1992). Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy 36, 387-93.
16. Woodley, C. L. & Kilburn, J. O. (1982). In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin. American Review of Respiratory Disease 126, 586-7.
17. Dickinson, J. M. & Mitchison, D. A. (1987). In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 68, 177-82.
18. Grassi, C. & Peona, V. (1995). New drugs for tuberculosis. European Respiratory Journal 8, Suppl. 20, 714S-8S.
19. Luna-Herrera, J., Reddy, M. V. & Gangadharam, P. R. (1995). In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy 39, 440-4.
20. Kapur, V., Li, L. L., lordanescu, S., Hamrick, M. R., Wanger, A., Kreiswirth, B. N. et al. (1994). Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta-subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. Journal of Clinical Microbiology 32, 1095-8.
21. Ohno, H., Koga, H., Kohno, S., Tashiro, T. & Hara, K. (1996). Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrobial Agents and Chemotherapy 40, 1053-6.
22. Telenti, A., Imboden, P., Marchesi, F., Lowrie, D., Cole, S., Colston, M. J. et al. (1993). Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 341, 647-50.
23. Williams, D. L., Waguespack, C., Eisenach, K., Crawford, J. T., Portaels, F., Salfinger, M. et al. (1994). Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrobial Agents and Chemotherapy 38, 2380-6.
24. Wallace, R. J., Nash, D. R., Steele, L. C. & Steingrube, V. (1986). Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. Journal of Clinical Microbiology 24, 976-81.
25. Miyazaki, Y., Koga, H., Kohno, S. & Kaku, M. (1993). Nested polymerase chain reaction for detection of Mycobacterium tuberculosis in clinical samples. Journal of Clinical Microbiology 31, 2228-32.
26. Ohno, H., Koga, H., Kuroita, T., Tomono, K., Ogawa, K., Yanagihara, K. et al. (1997). Rapid prediction of rifampin susceptibility of Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine 155, 2057-63.
27. Maddix, D. S., Tallian, K. B. & Mead, P. S. (1994). Rifabutin: a review with emphasis on its role in the prevention of disseminated Mycobacterium avium complex infection. Annals of Pharmacotherapy 28, 1250-4.
28. Moghazeh, S. L., Pan, X., Arain, T., Stover, C. K., Musser, J. M. & Kreiswirth, B. N. (1996). Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrobial Agents and Chemotherapy 40, 2655-7.
29. Reddy, M. V., Luna-Herrera, J., Daneluzzi, D. & Gangadharam, P. R. (1996). Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tubercle and Lung Diseases 77, 154-9.
30. Hirata, T., Saito, H., Tomioka, H., Sato, K., Jidoi, J., Hosoe, K. et al. (1995). In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 39, 2295-303.
31. Fujii, K., Saito, H., Tomioka, H., Mae, T. & Hosoe, K. (1995). Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrobial Agents and Chemotherapy 39, 1489-92.
32. Bodmer, T., Zurcher, G., Imboden, P. & Telenti, A. (1995). Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy 35, 345-8.
33. Jin, D. J. & Gross, C. A. (1988). Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. Journal of Molecular Biology 202, 45-58.
34. Lisitsyn, N. A., Sverdlov, E. D., Moiseyeva, E. P., Danilevdkaya, O. N. & Nikiforov, V. G. (1984). Mutation to rifampicin resistance at the beginning of the RNA polymerase β-subunit gene in Escherichia coli. Molecular and General Genetics 196, 173-4.
35. Musser, J. M. (1995). Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clinical Microbiology Reviews 8, 496-514.
36. Grassi, C. & Peona, V. (1996). Use of rifabutin in the treatment of pulmonary tuberculosis. Clinical Infectious Diseases 22, Suppl. 1, 550-4.